IntelGenx partners with atai Life Sciences
On May 14, 2021, IntelGenx Technologies Corp. reported that the previously announced US$12,346,300 investment by ATAI Life Sciences AG (“atai”) in its wholly owned subsidiary, IntelGenx Corp. (“IntelGenx”) is now completed. As a result of the investment, atai now holds approximately 25% of the issued and outstanding common stock of IntelGenx.
The investment was made as part of the strategic partnership agreement, under which IntelGenx will exclusively partner with atai to develop compounds for the prevention or treatment of mental health diseases or disorders, including compounds that have psychedelic, entactogenic and/or oneirophrenic properties.
Further information can be found on Globe Newswire’s website.
IntelGenx is a leading drug delivery company focused on the development and manufacturing of pharmaceutical films. IntelGenx’s superior film technologies, including VersaFilm®, DisinteQ™, VetaFilm™ and transdermal VevaDerm™, allow for next generation pharmaceutical products that address unmet medical needs.
atai is a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders.